These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 31378250)

  • 1. Nitric oxide: Antidepressant mechanisms and inflammation.
    Ghasemi M
    Adv Pharmacol; 2019; 86():121-152. PubMed ID: 31378250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic role of nitrergic neurotransmission in mood disorders.
    Ghasemi M; Claunch J; Niu K
    Prog Neurobiol; 2019 Feb; 173():54-87. PubMed ID: 29890213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune System Modulators with Antidepressant Effects: Evidence from Animal Models.
    Abelaira HM; Maciel AL; Quevedo J; Reus GZ
    CNS Neurol Disord Drug Targets; 2017; 16(4):398-406. PubMed ID: 28393713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide and major depression.
    Dhir A; Kulkarni SK
    Nitric Oxide; 2011 Apr; 24(3):125-31. PubMed ID: 21335097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Wistar-Kyoto rat model of endogenous depression: A tool for exploring treatment resistance with an urgent need to focus on sex differences.
    Millard SJ; Weston-Green K; Newell KA
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jul; 101():109908. PubMed ID: 32145362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: effect of antidepressants.
    Martín-Hernández D; Caso JR; Javier Meana J; Callado LF; Madrigal JLM; García-Bueno B; Leza JC
    J Neuroinflammation; 2018 Sep; 15(1):251. PubMed ID: 30180869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant Expression of Intracellular let-7e, miR-146a, and miR-155 Correlates with Severity of Depression in Patients with Major Depressive Disorder and Is Ameliorated after Antidepressant Treatment.
    Hung YY; Wu MK; Tsai MC; Huang YL; Kang HY
    Cells; 2019 Jun; 8(7):. PubMed ID: 31252530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel investigational drugs targeting IL-6 signaling for the treatment of depression.
    Fonseka TM; McIntyre RS; Soczynska JK; Kennedy SH
    Expert Opin Investig Drugs; 2015 Apr; 24(4):459-75. PubMed ID: 25585966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNFAIP3, a negative regulator of the TLR signaling pathway, is a potential predictive biomarker of response to antidepressant treatment in major depressive disorder.
    Hung YY; Lin CC; Kang HY; Huang TL
    Brain Behav Immun; 2017 Jan; 59():265-272. PubMed ID: 27640899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 5-HT
    Tiger M; Varnäs K; Okubo Y; Lundberg J
    Psychopharmacology (Berl); 2018 May; 235(5):1317-1334. PubMed ID: 29546551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible involvement of L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride.
    Kulkarni SK; Dhir A
    Eur J Pharmacol; 2007 Aug; 569(1-2):77-83. PubMed ID: 17585901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs.
    Quesseveur G; Gardier AM; Guiard BP
    Curr Drug Targets; 2013 Oct; 14(11):1277-94. PubMed ID: 24020973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders.
    Fakhoury M
    Mol Neurobiol; 2016 Jul; 53(5):2778-2786. PubMed ID: 25823514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Depressive symptoms during anorexia nervosa: State of the art and consequences for an appropriate use of antidepressants].
    Leblé N; Radon L; Rabot M; Godart N
    Encephale; 2017 Feb; 43(1):62-68. PubMed ID: 27452149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric Oxide and Major Depressive Disorder: Pathophysiology and Treatment Implications.
    Kudlow P; Cha DS; Carvalho AF; McIntyre RS
    Curr Mol Med; 2016; 16(2):206-15. PubMed ID: 26812915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the PACAP signaling system in depression.
    Pinhasov A; Nesher E; Gross M; Turgeman G; Kreinin A; Yadid G
    Curr Pharm Des; 2011; 17(10):990-1001. PubMed ID: 21524254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychopharmacological Approaches for Neural Plasticity and Neurogenesis in Major Depressive Disorders.
    Matar D; Serhan A; El Bilani S; Faraj RA; Hadi BA; Fakhoury M
    Adv Exp Med Biol; 2024; 1456():27-48. PubMed ID: 39261422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major depressive disorder: remission of associated symptoms.
    Trivedi MH
    J Clin Psychiatry; 2006; 67 Suppl 6():27-32. PubMed ID: 16848674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
    Hillhouse TM; Porter JH
    Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.